Halozyme Therapeutics Inc. (HALO) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Halozyme Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Halozyme Therapeutics Inc. (HALO) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $14.6B. It trades at $130.03, up 1.19% today. 7 analysts' average target of $105.86 implies −18.6% from today's price. Kronos AI's 30-day forecast is −34.4% (0 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $105.86 |
| Low – high | $78.00 – $130.00 |
| Analysts | 7 |
| Upside to average | −18.6% |
Kronos AI 30-day forecast
| Expected close | $84.28 (−34.4%) |
| Likely range | −41.3% … −32.5% |
| As of | 2026-10-27 |
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator